Actinium Pharmaceuticals Announces Publication of Results from the Phase 3 SIERRA Trial of Iomab-B in the Journal of Clinical Oncology
Iomab-B is the first CD45 targeted radiotherapy for conditioning in development to enable potentially curative bone marr...